- NYSEAMERICAN:TRXC finished the day in the red after rising nearly 30% at one point.
- Transenterix received European approval for its Intelligent Surgical Unit.
- Investors are hoping Transenterix can get a share of the nearly 6 million annual laparoscopic surgeries in the U.S. and Europe.
NYSEAMERICAN:TRXC had another rollercoaster trading session as shares surged by nearly 30% to start the day but eventually hit the red by the closing bell. This is not uncommon to see, especially with small-cap healthcare stocks which are known to be extremely volatile when good or bad news hits. Taking a look at Transenterix’s daily trading volume shows that nearly 97 million shares changed hands today, which is about six times the average daily trading volume of 16 million shares. The stock did briefly hit a new 52-week high of $4.44, before setting back down to $3.47 at the end of trading hours.
The catalyst was European approval for Transenterix’s Intelligent Surgical Unit or ISU, which provides improved machine-vision functionality for its Senhance system which specializes in laparoscopic surgeries. Any improvement to robotic vision can only be seen as a positive when it comes to performing surgeries, so it stands to reason as to why investors have shown such excitement as of late. There are an estimated 6 million laparoscopic procedures that take place every year in both the United States and Europe, so the market for the Senhance system seems ripe for the picking.
TRXC stock forecast
The sudden swing in TRXC looks to be investors skimming some profits from the recent bull run as the stock begins to consolidate some of its momentum. What does this mean for the future? It is difficult to say as a fuller buy-in for robotic surgeries is still needed even if the equipment has received approvals but if industry-leader Intuitive Surgical (NASDAQ:ISRG) is any indication of how well robotics companies can do, TRXC may be in for an extended period of gains.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.